Literature DB >> 28417345

Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.

Suradech Suthiphosuwan1,2, David Kim1,3, Aditya Bharatha2, Jiwon Oh4,5.   

Abstract

OPINION STATEMENT: Multiple sclerosis (MS) is an immune-mediated disease affecting the central nervous system (CNS). Magnetic resonance imaging (MRI) has long been recognized as an important tool in the diagnosis of MS. It is increasingly recognized that in addition to its role in diagnosis, MRI can play a key role as a noninvasive tool for prognostication, disease monitoring, assessment of treatment efficacy, and safety monitoring of disease-modifying therapies (DMTs). A confluence of factors, including increased availability of MRI, development of improved MRI techniques, and increased availability of DMTs have contributed to the expanding role of MRI in MS clinical care. As the clinical use of MRI in MS expands, it is important that MRI protocols amongst clinical centers are standardized. Here, we summarize recent evidence supporting the use of MRI in clinical practice, summarize various clinical guidelines and recommendations for the use of MRI in MS disease monitoring, and provide our recommendations for standardized MRI protocols.

Entities:  

Keywords:  Disease monitoring; MRI; Multiple sclerosis; Safety; Standardized protocols; Treatment efficacy

Year:  2017        PMID: 28417345     DOI: 10.1007/s11940-017-0453-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  75 in total

1.  Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Authors:  J Kuhle; G Disanto; R Dobson; R Adiutori; L Bianchi; J Topping; J P Bestwick; U-C Meier; M Marta; G Dalla Costa; T Runia; E Evdoshenko; N Lazareva; E Thouvenot; P Iaffaldano; V Direnzo; M Khademi; F Piehl; M Comabella; M Sombekke; J Killestein; H Hegen; S Rauch; S D'Alfonso; J C Alvarez-Cermeño; P Kleinová; D Horáková; R Roesler; F Lauda; S Llufriu; T Avsar; U Uygunoglu; A Altintas; S Saip; T Menge; C Rajda; R Bergamaschi; N Moll; M Khalil; R Marignier; I Dujmovic; H Larsson; C Malmestrom; E Scarpini; C Fenoglio; S Wergeland; A Laroni; V Annibali; S Romano; A D Martínez; A Carra; M Salvetti; A Uccelli; Ø Torkildsen; K M Myhr; D Galimberti; K Rejdak; J Lycke; J L Frederiksen; J Drulovic; C Confavreux; D Brassat; C Enzinger; S Fuchs; I Bosca; J Pelletier; C Picard; E Colombo; D Franciotta; T Derfuss; Rlp Lindberg; Ö Yaldizli; L Vécsei; B C Kieseier; H P Hartung; P Villoslada; A Siva; A Saiz; H Tumani; E Havrdová; L M Villar; M Leone; N Barizzone; F Deisenhammer; C Teunissen; X Montalban; M Tintoré; T Olsson; M Trojano; S Lehmann; G Castelnovo; S Lapin; R Hintzen; L Kappos; R Furlan; V Martinelli; G Comi; S V Ramagopalan; G Giovannoni
Journal:  Mult Scler       Date:  2015-02-13       Impact factor: 6.312

2.  A method for evaluating treatment switching criteria in multiple sclerosis.

Authors:  Brian C Healy; Bonnie I Glanz; James Stankiewicz; Guy Buckle; Howard Weiner; Tanuja Chitnis
Journal:  Mult Scler       Date:  2010-08-24       Impact factor: 6.312

3.  European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors:  G Comi; M Filippi; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

4.  Scoring treatment response in patients with relapsing multiple sclerosis.

Authors:  M P Sormani; J Rio; M Tintorè; A Signori; D Li; P Cornelisse; B Stubinski; M l Stromillo; X Montalban; N De Stefano
Journal:  Mult Scler       Date:  2012-09-25       Impact factor: 6.312

5.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

Authors:  Francois Cotton; Howard L Weiner; Ferenc A Jolesz; Charles R G Guttmann
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

6.  Defining interferon beta response status in multiple sclerosis patients.

Authors:  Richard A Rudick; Jar-Chi Lee; Jack Simon; Richard M Ransohoff; Elizabeth Fisher
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

Review 7.  Treatment optimization in MS: Canadian MS Working Group updated recommendations.

Authors:  Mark S Freedman; Daniel Selchen; Douglas L Arnold; Alexandre Prat; Brenda Banwell; Michael Yeung; David Morgenthau; Yves Lapierre
Journal:  Can J Neurol Sci       Date:  2013-05       Impact factor: 2.104

8.  Early MRI in optic neuritis: the risk for disability.

Authors:  J K Swanton; K T Fernando; C M Dalton; K A Miszkiel; D R Altmann; G T Plant; A J Thompson; D H Miller
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

9.  Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Authors:  Anthony Traboulsee; Laurent Létourneau-Guillon; Mark Steven Freedman; Paul W O'Connor; Aditya Bharatha; Santanu Chakraborty; J Marc Girard; Fabrizio Giuliani; John T Lysack; James J Marriott; Luanne M Metz; Sarah A Morrow; Jiwon Oh; Manas Sharma; Robert A Vandorpe; Talia Alexandra Vertinsky; Vikram S Wadhwa; Sarah von Riedemann; David K B Li
Journal:  Can J Neurol Sci       Date:  2015-04-21       Impact factor: 2.104

Review 10.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154

View more
  1 in total

Review 1.  The potential of serum neurofilament as biomarker for multiple sclerosis.

Authors:  Stefan Bittner; Jiwon Oh; Eva Kubala Havrdová; Mar Tintoré; Frauke Zipp
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.